RxDoctor Payments Data

Myrth Mehl

Nurse Practitioner · Norman, OKNPI 1609101583

Payments from drug & device makers

$1,261in general payments, 2019–2025

Across 66 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$181
  • Amgen$172
  • UCB, Inc.$146
  • GSK$137
  • Johnson & Johnson$120
  • Lilly USA, LLC$87
  • plus $418 from 11 others

What the payments were for

  • Food & beverage$1,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,261 in reported general payments places this provider in the 80th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$66,716
Medicare patients
432
Services billed
1,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept83$699,362
Humira(Cf) PenAdalimumab59$403,878
Xeljanz XrTofacitinib Citrate45$262,976
EnbrelEtanercept19$175,121
HumiraAdalimumab18$125,156
Orencia ClickjectAbatacept16$122,804
RinvoqUpadacitinib15$95,451
Humira PenAdalimumab12$80,312
OrenciaAbatacept13$74,650
XeljanzTofacitinib Citrate12$68,091
ForteoTeriparatide12$51,745
Teriparatide11$33,283
SavellaMilnacipran Hcl14$12,298
MethotrexateMethotrexate Sodium295$6,850
Hydroxychloroquine Sulfate150$5,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Rinvoq, Savella$181$232,90547 claims
AmgenEnbrel$172$175,12119 claims
E.r. Squibb & Sons, L.L.C.Orencia$31$74,65013 claims
PfizerXeljanz$34$68,09112 claims
Lilly USA, LLCForteo$87$51,74512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →